Financial Data and Key Metrics Changes - In Q4 2025, total revenue reached $3.2 billion, a 10% increase compared to Q4 2024, while full-year revenue was $12 billion, reflecting a 9% growth versus 2024 [32][33] - Non-GAAP net income for Q4 2025 was $1.3 billion, up 24% year-over-year, resulting in earnings per share of $5.03, a 26% increase compared to the prior year [37] - The company ended 2025 with $12.3 billion in cash, cash equivalents, and marketable securities, positioning it well for future investments [37] Business Line Data and Key Metrics Changes - Cystic fibrosis (CF) therapies generated full-year 2025 growth of 7% globally, with U.S. CF revenue growing 11% year-over-year [32][33] - CASGEVY achieved $54 million in revenue in Q4 and $116 million for the full year 2025, indicating strong patient initiations and first cell collections [34] - JOURNAVX delivered $27 million in sales in Q4 and $60 million for the full year, with significant growth in quarterly prescriptions since its launch [34][35] Market Data and Key Metrics Changes - The CF population has seen a 3% annual increase over the last five years, contributing to revenue growth [20] - In Europe, reimbursement for ALYFTREK has been secured in key countries, enhancing market access [21] - The company has engaged with payers covering over 210 million lives regarding the renal pipeline, indicating strong interest and education on IgAN [60] Company Strategy and Development Direction - The company aims to expand leadership in CF, accelerate adoption of CASGEVY, and grow JOURNAVX while advancing its renal franchise [6][29] - The renal pipeline is expected to rival the scale of the CF business, with a focus on patient-centric approaches and securing reimbursement [29][30] - The company is committed to serial innovation and comprehensive patient support programs to enhance access to its therapies [29][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver sustained growth through commercial execution and innovation [6] - The guidance for 2026 anticipates total revenue in the range of $12.95 billion to $13.1 billion, representing 8%-9% growth versus the prior year [38] - The company expects combined non-GAAP operating expenses to be in the range of $5.65 billion to $5.75 billion as it continues to invest in its late-stage clinical pipeline [39] Other Important Information - The company has initiated a rolling BLA submission for povetacicept in IgAN, with breakthrough therapy designation granted by the FDA [11][12] - The company plans to double the size of its field force for JOURNAVX in Q2 2026 to drive prescription growth [26] Q&A Session Summary Question: Concerns about hypogammaglobulinemia adverse events related to pove - Management indicated that while low IgG levels are expected, data from the RUBY-3 study showed no serious adverse events or infections associated with low IgG levels, suggesting a favorable benefit-risk profile [43][44] Question: Guidance details for CF component and ALYFTREK performance - Management provided total revenue guidance of $12.95 billion to $13.1 billion, with a non-CF contribution of $500 million or more, while noting strong international launch contributions for ALYFTREK [49][51][52] Question: Payer access and reimbursement for pove - Management reported positive engagements with payers, indicating strong interest in the product and ongoing discussions to ensure access [59][60] Question: Expected results on proteinuria for pove - Management emphasized the importance of proteinuria response magnitude, referencing RUBY-3 results as a benchmark for expected outcomes in the RAINIER trial [62][64] Question: Rationale for studying pove in generalized myasthenia gravis - Management highlighted the significant patient population and limitations of current treatments, positioning pove as a potentially superior option due to its mechanism of action [70][72]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue reached $3.2 billion, a 10% increase compared to Q4 2024. For the full year 2025, total revenue was $12 billion, reflecting a 9% increase versus 2024 [33] - Full year 2025 growth in cystic fibrosis (CF) therapies was 7% globally, with U.S. CF revenue growing 11% year-over-year [34] Business Line Data and Key Metrics Changes - CASGEVY generated $54 million in revenue in Q4 and $116 million for the full year 2025, with continued momentum in patient initiations and first cell collections [34] - JOURNAVX delivered $27 million in sales in Q4 and $60 million for the full year, showing substantial growth in quarterly prescriptions since its launch [34] Market Data and Key Metrics Changes - Internationally, CF revenue grew 2% year-over-year, driven by the penetration of KAFTRIO and contributions from ALYFTREK, partially offset by a $200 million decline in Russia sales [34] - The company secured reimbursement for ALYFTREK in key European countries, enhancing access for patients [21] Company Strategy and Development Direction - The company aims to expand leadership in CF, accelerate adoption of CASGEVY, and grow JOURNAVX while advancing its renal franchise, starting with povetacicept in IgAN [5] - The renal pipeline is expected to become a key growth engine, potentially rivaling the scale of the CF business [29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver sustained growth through commercial execution and innovation across multiple serious disease areas [5] - The guidance for 2026 anticipates total company revenue in the range of $12.95 billion to $13.1 billion, representing 8%-9% growth versus the prior year [39] Other Important Information - The company ended 2025 with $12.3 billion in cash, cash equivalents, and marketable securities, positioning it well for future investments [38] - The fourth quarter gross margin was 85.7%, reflecting the product mix and investments in manufacturing optimization [35] Q&A Session Summary Question: Concerns about hypogammaglobulinemia adverse events related to povetacicept - Management indicated that while BAFF/APRIL inhibitors may decrease IgG levels, data from the RUBY-3 study showed no serious adverse events or infections associated with low IgG levels, suggesting a favorable benefit-risk profile [44][45] Question: Guidance details for CF component relative to ALYFTREK and TRIKAFTA - Management provided total revenue guidance of $12.95 billion to $13.1 billion, with a non-CF contribution of $500 million or more, but did not break down specifics for ALYFTREK versus other products [52] Question: Payer access and reimbursement for povetacicept - Management reported positive engagement with payers, having conducted 74 engagements covering over 210 million lives, indicating strong interest in the upcoming products [62] Question: Expected results on proteinuria for povetacicept - Management highlighted that a significant reduction in proteinuria, similar to the RUBY-3 study results, would be clinically meaningful and important for long-term outcomes [66] Question: Mix between retail and hospital settings for JOURNAVX - Management noted that the prescription mix concluded at about 50/50 between retail and hospital settings in 2025, with expectations for a shift towards retail in the future [83]

FIRST QUARTER 2025 FINANCIAL RESULTS Fourth Quarter and Full Year 2025 Financial Results ©2026 Vertex Pharmaceuticals Incorporated ©2026 Vertex Pharmaceuticals Incorporated ©2025 Vertex Pharmaceuticals Incorporated Presentation intended for the investment community Agenda Introduction Susie Lisa, CFA, Senior Vice President, Investor Relations CEO Perspective and Pipeline Update February 12, 2026 Reshma Kewalramani, M.D., Chief Executive Officer and President Commercial Update Duncan McKechnie, Executive Vic ...

Core Viewpoint - Vertex Pharmaceuticals forecasts 2026 revenue largely in line with analysts' estimates, driven by growth in cystic fibrosis treatments and contributions from newer products [1] Group 1: Revenue Forecast - The company anticipates revenue for 2026 to align closely with analyst expectations [1] - Growth is expected primarily from cystic fibrosis treatments [1] Group 2: Product Contributions - Newer products are also expected to contribute to the revenue growth [1]

Financial Performance - Full year total revenue for 2025 was $12.0 billion, a 9% increase compared to 2024; fourth quarter total revenue was $3.19 billion, a 10% increase compared to Q4 2024[1][3][8] - In the U.S., total revenue for 2025 increased 13% to $7.55 billion, driven by strong CF patient demand and higher realized net prices[3][8] - Vertex reported total revenues of $3,190.0 million for the three months ended December 31, 2025, an increase of 9.6% compared to $2,912.0 million for the same period in 2024[40] - GAAP net income for Q4 2025 was $1.2 billion, compared to $913 million in Q4 2024, primarily driven by increased product revenue[7] - Vertex's net income for the twelve months ended December 31, 2025, was $3,953.2 million, compared to a net loss of $535.6 million for the same period in 2024[40] - GAAP operating income for Q4 2025 was $1,205.9 million, compared to $1,026.0 million in Q4 2024, representing a 17.5% increase[48] - Non-GAAP operating income for the twelve months ended December 31, 2025 was $5,263.1 million, up from $695.6 million in 2024, indicating a significant growth[48] - GAAP net income for the twelve months ended December 31, 2025 was $3,953.2 million, compared to a net loss of $535.6 million in 2024[48] - Cash, cash equivalents, and marketable securities increased to $6,608.1 million as of December 31, 2025, from $6,115.9 million in 2024, showing a growth of 8.1%[51] - Total assets rose to $25,643.0 million in 2025, up from $22,533.2 million in 2024, reflecting a 13.4% increase[51] Revenue Guidance and Expectations - The company provides full year 2026 total revenue guidance of $12.95 billion to $13.1 billion, with non-CF products expected to contribute $500 million or more in revenue[1][13][14] - Vertex's financial guidance for combined GAAP R&D, AIPR&D and SG&A expenses in 2026 is $6.3 to $6.45 billion, including approximately $100 million of anticipated AIPR&D expenses[14][15] - The company anticipates over $500 million in non-CF product revenue in 2026, indicating a focus on expanding its product portfolio[54] Product Development and Approvals - Vertex expects to submit for approval of ALYFTREK in children 2 to 5 years of age in the first half of 2026, following positive pivotal study results[18] - Vertex initiated the rolling BLA filing for U.S. accelerated approval of povetacicept in IgAN in Q4 2025, with interim analysis data expected in the first half of 2026[24][27] - The company expects to complete the Phase 2 portion of the OLYMPUS study for povetacicept in mid-2026, with the Phase 3 portion anticipated to start thereafter[30] - Vertex plans to initiate a Phase 2 proof-of-concept study for povetacicept in gMG in the first half of 2026[30] - Vertex completed enrollment in the AMPLITUDE Phase 2/3 trial of inaxaplin and expects to share interim analysis data in late 2026 or early 2027[30] - The AGLOW study, evaluating VX-407 in patients with specific PKD1 gene variants, is expected to complete enrollment by the end of 2026, targeting approximately 30,000 patients[36] Research and Development Expenses - Combined GAAP and non-GAAP R&D, Acquired IPR&D and SG&A expenses for Q4 2025 were $1.52 billion and $1.36 billion, respectively, compared to $1.46 billion and $1.30 billion in Q4 2024[4] - Vertex's combined non-GAAP R&D, AIPR&D, and SG&A expenses for the twelve months ended December 31, 2025, were $5,118.2 million, a decrease from $8,821.7 million in 2024[46] Strategic Partnerships and Coverage - Vertex secured commercial coverage for JOURNAVX with all three national PBMs, providing access for over 200 million individuals across commercial and government payers[20] - The company has received multiple designations for zimislecel, including RMAT and Fast Track from the FDA, and PRIME from the EMA[30] - Vertex entered into an exclusive global license agreement with WuXi Biologics for the development of a trispecific T cell engager for autoimmune diseases, currently in preclinical development[35] Product Revenue Performance - Product revenues from TRIKAFTA/KAFTRIO were $2,572.5 million for the three months ended December 31, 2025, a decrease of 5.4% from $2,720.8 million in the same period of 2024[43] - Expectations for continued growth in cystic fibrosis (CF) treatments include increasing patient access through new approvals and reimbursement agreements[54]

Core Insights - Vertex, Inc. is a leading provider of indirect tax solutions globally, offering comprehensive software and services for tax compliance management [1] - Jefferies has set a price target of $16 for Vertex, indicating a potential price increase of approximately 24.71% from the current price of $12.83, reflecting confidence in the company's growth prospects [2][6] - Vertex reported double-digit revenue growth and improved profitability for the year ending December 31, 2025, with significant growth in its e-invoicing business, positioning the company well for future expansion [3][6] Financial Performance - The current stock price of Vertex is $12.83, representing a 13.78% decrease with a change of $2.05, while the market capitalization is approximately $2.05 billion [4] - The stock has fluctuated between $12.40 and $15.68 today, with a 52-week high of $52.74, indicating potential for recovery [4] - The trading volume for VERX is 7,817,750 shares on the NASDAQ exchange, reflecting active investor interest [5] Management Outlook - Christopher Young, Vertex's President and CEO, expressed optimism about accelerating revenue growth and enhancing profitability, driven by favorable near-term growth factors [5]

Core Viewpoint - Jefferies has downgraded Vertex, Inc. from a Buy to a Hold, indicating a more conservative outlook on the stock's future performance [1] Financial Performance - Vertex's Q4 2025 earnings call revealed financial outcomes, including revenue and profit margins, which contributed to the downgrade by Jefferies [2] - Following the earnings report and the downgrade, Vertex's stock declined by 13.78%, dropping by $2.05 [2] Stock Volatility - Vertex's shares have shown significant volatility, with a daily trading range between $12.40 and $15.68 [3] - Over the past year, the stock reached a peak of $52.74 and a low of $12.40, reflecting investor sensitivity to operational changes and market dynamics [3] Market Presence - The current market capitalization of Vertex is approximately $2.05 billion, indicating a substantial presence in the market [4] - Vertex has a trading volume of 7.82 million shares on the NASDAQ exchange, attracting investor attention despite recent challenges [4]

Summary of Entrada Therapeutics Conference Call Company Overview - **Company**: Entrada Therapeutics (NasdaqGM:TRDA) - **Focus**: Development of intracellular therapeutics, particularly for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) [4][6] - **Location**: Boston, with approximately 150-160 employees [4] - **New Initiatives**: Recently entered the ocular disease space, focusing on inherited retinal diseases, starting with Usher syndrome type 1A [4] Key Data Inflection Points - **Clinical Data Releases**: - Q2 2026: First clinical data set for ENTR-601-44 program at a 6 mg/kg dose, expected to show double-digit dystrophin levels and reestablish safety [6][10] - End of 2026: Data for 12 mg/kg dose from exon 44 and additional data from exon 45 [5][7] - Vertex's DM1 program data expected mid-2026 [7] Safety and Efficacy - **Safety Database**: Established a robust safety database from non-clinical studies and healthy volunteer data [6][9] - **Dystrophin Levels**: Aiming for double-digit dystrophin levels, with confidence based on extensive non-clinical data [9][10] - **Comparison with Peers**: Expecting to outperform Avidity's del-zota data, which established roughly 25% dystrophin levels above background [10] Competitive Landscape - **Differentiation**: Entrada's cyclic cell-penetrating peptide delivery mechanism is distinct from competitors like PepGen and Sarepta, which have faced safety liabilities [11][12] - **Regulatory Flexibility**: FDA has allowed dose escalation up to 18 mg/kg, indicating a favorable therapeutic index compared to competitors [13] Functional Data and Patient Outcomes - **Functional Benefit Measurement**: While initial data will focus on safety and dystrophin production, functional benefits are expected to be assessed in later cohorts [15][18] - **Background Dystrophin Levels**: Patients in the exon 44 cohort have 6%-9% background dystrophin, which may delay observable functional benefits [16][18] U.S. Study Enrollment - **FDA Approval**: Currently approved to enroll an adult study in the U.S. with plans to start in the second half of 2026, contingent on Q2 data [24][25] - **Dose Considerations**: Current U.S. study doses capped at 1.28 mg/kg, with potential discussions for higher doses based on new data [25][27] Future Exon Programs - **Pipeline Expansion**: The same endosomal escape vehicle (EEV) technology will be used for future exons (45, 50, 51), which is expected to de-risk these programs [30][31] - **Market Potential**: Aiming to capture a significant portion of the estimated $5 billion U.S. market for DMD treatments [35] Conclusion - **Strategic Positioning**: Entrada Therapeutics is positioned to leverage its unique delivery mechanism and extensive non-clinical data to establish itself in the DMD and DM1 markets, with a focus on safety, efficacy, and patient outcomes [41][42]

Summary of Stoke Therapeutics Conference Call Company Overview - **Company**: Stoke Therapeutics (NasdaqGS:STOK) - **Focus**: Development of treatments for genetic diseases, specifically Dravet syndrome and Autosomal Dominant Optic Atrophy (ADOA) [2][6] Key Points on Dravet Syndrome - **Disease Understanding**: Dravet syndrome is a severe form of epilepsy affecting young children, leading to significant developmental challenges [2][3] - **Clinical Data**: Initial phase 1/2 data showed an 80% reduction in seizures on top of standard care medications, with durable effects observed over nearly four years [4][9] - **Cognitive and Behavioral Benefits**: Improvements in cognition and behavior were noted, measured by the Vineland-3 assessment, indicating potential for neurodevelopmental progress in children who typically plateau after 18 months [5][10] - **Phase 3 Program**: Enrollment for the phase 3 study is expected to complete in Q2 2026, with data anticipated in mid-2027 [6][28] Market Opportunity - **Patient Population**: Approximately 36,000-40,000 patients globally, with 16,000 in the U.S. and 6,000 currently addressable [50][51] - **Pricing Strategy**: The company aims to position its treatment as a disease-modifying therapy, potentially aligning pricing with similar therapies like Spinraza [52][54] Regulatory Pathway - **FDA Interaction**: The company is pursuing accelerated approval but faced challenges due to the FDA's request for additional data. A follow-up discussion is planned to present data against patient baseline rather than cross-study comparisons [34][35][36] - **Optimal Label**: The goal is to achieve a label that reflects both seizure reduction and cognitive improvements, which is crucial for market positioning and pricing discussions [41][42] ADOA Development - **New Indication**: The first patient for ADOA was dosed recently, targeting a genetic loss of eyesight by upregulating the OPA1 gene to improve mitochondrial function and vision [56][57] - **Market Size**: The ADOA market is estimated at around 16,000 patients in the top seven geographies [58] Financial Position - **Cash Reserves**: The company reported approximately $400 million in cash at the end of 2025, with funding from Biogen covering 30% of Dravet R&D costs, providing a runway into 2028 [60]

Core Insights - The software and technology sectors have rapidly shifted from being highly attractive investment areas to ones that are perceived as risky, with many software stocks losing billions in market value due to widespread panic [1] Group 1: Market Trends - The deterioration of the software and technology sectors has occurred within a few months, indicating a significant market shift [1] - Many software stocks have experienced substantial declines, shedding billions in market value [1] Group 2: Analyst Background - Gary Alexander has extensive experience in covering technology companies on Wall Street and working in Silicon Valley, providing insights into current industry themes [1] - He has been a contributor to Seeking Alpha since 2017 and has been quoted in various web publications, indicating his influence and reach in the investment community [1]